We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

DRG International, Inc.

DRG International, a global innovator of high-quality medical diagnostics and equipment, provides the medical and res... read more Featured Products: More products

Download Mobile App





DRG Group Presents New Analyzer and ELISAs at Dubai Lab Exhibition

By LabMedica International staff writers
Posted on 08 Feb 2017
The DRG Group, a leading medical diagnostic and laboratory equipment supplier, demonstrated its fully automated random access analyzer, DRG:HYBRiD-XL, along with its newest ELISAs, at MEDLAB 2017, the world’s largest laboratory exhibition and congress in the Middle East.

The DRG:HYBRiD-XL is a fully automated, continuous access analyzer that allows the simultaneous measurement of immunoassays and clinical chemistry parameters, including turbidimetric tests in one sample. More...
It allows medical practitioners to carry out up to 40 tests of different types or 40 times of the same test, or up to 20-patient samples over a wide range of pre-packaged tests to serve different specialties.

DRG also highlighted its newest ELISAs such as Salivary Progesterone HS (High Sensitivity) ELISA, DHT-optimized and Hepcidin 25 (bioactive) HS ELISA kit at MEDLAB 2017. The company’s saliva diagnostics products offer several benefits such as non-invasive sampling, measurement of the free (unbounded) fraction of steroids, and much higher diagnostic relevance with reproducible and reliable results, compared to serum analytics. DRG’s new Salivary Progesterone HS ELISA is calibrated against mass spectrometry, which is considered as gold standard in saliva diagnostics.


New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
New
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.